Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): Delivery by SV40 provides durable protection against HIV-1 and does not require selection

Gene Therapy

Volumn 6, Issue 4, 1999, Pages 660-666

  BouHamdan, M ^a   Duan, L X ^a   Pomerantz, R J ^a   Strayer, D S ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Gene therapy; HIV 1; Intracellular immunization; SV 40

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOGLOBULIN FRAGMENT; INTEGRASE; VIRUS ENZYME;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TYPING; WESTERN BLOTTING;

BLOTTING, WESTERN; CELLS, CULTURED; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LEUKEMIA VIRUS, MURINE; SIMIAN VIRUS 40; T-LYMPHOCYTES; TRANSFECTION; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MURINE LEUKEMIA VIRUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0032938325     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300864     Document Type: Article

References (38)

1. Morsy MA, Mitani K, Clemens P, Caskey CT. Progress toward gene therapy. J Am Med Assn 1993; 270: 2338-2344.
2. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Meth Enzymol 1993; 217: 581-599.
3. Mulligan RC. The basic science of gene therapy (review). Science 1993; 260: 926-932.
4. Strayer DS. SV40 as an effective gene transfer vector in vivo. J Biol Chem 1996; 271: 24741-24746.
5. Strayer DS, Kondo R, Milano J, Duan L-X. Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Therapy 1997; 4: 219-225.
6. Strayer DS, Milano J. SV40 mediates stable gene transfer in vivo. Gene Therapy 1996; 3: 581-587.
7. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 1992; 56: 375-394.
8. Debouck C. The HIV-1 protease as a therapeutic target for AIDS (review). AIDS Res Hum Retrovir 1992; 8: 153-164.
9. Miller RH et al. Conference summary: novel HIV therapies -from discovery to clinical proof of concept. AIDS Res Hum Retrovir 1996; 12: 859-865.
10. Ridky T, Leis J. Development of drug resistance to HIV-1 protease inhibitors (Review). J Biol Chem 1995; 270: 29621-29623.
11. Richman DD. Clinical significance of drug resistance in human immunodeficiency virus (Review). Clin Infect Dis 1995; 21: S166-S169.
12. Dropulic B, Jeang KT. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention (review). Hum Gene Ther 1994; 5: 927-939.
13. Pomerantz RJ, Trono D. Genetic therapies for HIV infections: promise for the future (editorial) (review). AIDS 1995; 9: 985-993.
14. Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci USA 1994; 91: 5932-5936.
15. Duan L-X et al. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994; 91: 5075-5079.
16. Duan L-X, Pomerantz RJ. Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HIV-1 infections. Nucleic Acids Res 1994; 22: 5433-5438.
17. Duan L-X et al. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains (published erratum appears in Hum Gene Ther 1997; 8: 510). Hum Gene Ther 1994; 5: 1315-1324.
18. Duan L-X, Zhu M, Bagasra O, Pomerantz RJ. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum Gene Ther 1995; 6: 1561-1573.
19. Duan L-X, Pomerantz RJ. Intracellular antibodies for HIV-1 gene therapy. Sci Med 1997; 3: 24-33.
20. Levy-Mintz P et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol 1996; 70: 8821-8832.
21. Lisziewicz J, Sun D, Lisziewicz A, Gallo RC. Anti-Tat gene therapy: a candidate for late-stage AIDS patients. Gene Therapy 1995; 2: 218-222.
22. Liu J, Woffendin C, Yang ZY, Nabel GJ. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Therapy 1994; 1: 32-37.
23. + T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther 1998; 9: 487-496.
24. Shaheen F et al. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol 1996; 70: 3392-3400.
25. Sun LQ et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci USA 1995; 92: 7272-7276.
26. Yu M et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 (published erratum appears in Proc Natl Acad Sci USA 1993; 90: 8303). Proc Natl Acad Sci USA 1993; 90: 6340-6344.
27. Wu Y et al. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition (published correction appears in 1998; 72: 3505). J Virol 1996; 70: 3290-3297.
28. Katz RA, Skalka AM. The retroviral enzymes (review). Ann Rev Biochem 1994; 63: 133-173.
29. Bukrinsky M, Sharova N, Stevenson M. Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. J Virol 1993; 67: 6863-6865.
30. Kondo R, Feitelson MA, Strayer DS. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Therapy 1998; 5: 575-582.
31. Butel JS, Jarvis DL. The plasma-membrane-associated form of SV40 large tumor antigen: biochemical and biological properties. Biochem Biophys Acta 1986; 865: 171-195.
32. Cicurel L, Croce CM. Antibody response to simian virus 40 tumor antigen in nude mice reconstituted with T cells. J Immunol 1977; 119: 850-854.
33. Crawford LV, Pim DC, Lane DP. An immunochemical investigation of SV40 T-antigens. 2. Quantitation of antigens and antibody activities. Virology 1980; 100: 314-325.
34. Law LW, Takemoto KK, Rogers MJ, Ting RC. Induction of simian virus 40 (SV40) transplantation immunity in mice by SV40-transformed cells of various species. J Natl Cancer Inst 1977; 59: 1523-1526.
35. Tevethia S. Characterization of hamster antibody reacting with papovavirus SV40 tumor antigen. J Immunol 1967; 98: 1257-1264.
36. Rund D et al. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions. Hum Gene Ther 1998; 9: 649-657.
37. Embretson J et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-362.
38. Strayer DS et al. Titering replication-defective virus for use in gene transfer. BioTechniques 1997; 22: 447-450.